ABT-333 is primarily used in the treatment of hepatitis C virus (HCV) infections. It functions as a non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. By inhibiting this enzyme, ABT-333 effectively reduces viral load in infected individuals. It has been studied in combination with other antiviral agents, such as ABT-267 and ABT-450, to enhance efficacy and reduce the likelihood of drug resistance. This combination approach is part of all-oral direct-acting antiviral regimens that offer high cure rates with shorter treatment durations and improved safety profiles compared to older interferon-based therapies. ABT-333 plays a key role in advancing curative treatments for chronic hepatitis C, particularly in genotype 1 infections.